HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV)
HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV) Produktliste
- Attribut
Protein (2)
- Produktbibliothek
Online (2)
- Spezies
Human (2)
- Etikett
His Tag & Avi Tag (1)His Tag (1)
- Marker
Biotin-labeled (1)Unconjugated (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
HOT HL1-H82E4 |  Human | HEK293 | Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein (Monomer, MALS & SPR verified) |  |  |  In den Warenkorb legen | |
| Human | HEK293 | Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (MALS & SPR verified) | | | In den Warenkorb legen |
Gesamtmenge2
- 1
HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV) Molekülhintergrund
NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A*0201 NY-ESO-1 (SLLMWITQV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.
- Produktliste